BMO Capital analyst Juan C. Sanabria upgraded Ventas (VTR – Research Report) to Buy today and set a price target of $67.00. The company’s shares closed last Thursday at $58.86, close to its 52-week high of $61.09.
According to TipRanks.com, Sanabria is a 3-star analyst with an average return of 4.2% and a 58.3% success rate. Sanabria covers the Financial sector, focusing on stocks such as Retail Opportunity Investments, National Storage Affiliates, and Healthcare Trust of America.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ventas with a $60.22 average price target, which is a 5.0% upside from current levels. In a report issued on February 24, Mizuho Securities also maintained a Buy rating on the stock.
Ventas’ market cap is currently $24.19B and has a P/E ratio of 450.34.
Based on the recent corporate insider activity of 88 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VTR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ventas, Inc. engages in the acquisition and ownership of seniors housing and healthcare properties. The company invests in seniors housing and healthcare properties through acquisitions and leases its properties to unaffiliated tenants or operate them through independent third-party managers. It operates through the following segments: Triple-Net Leased Properties, Senior Living Operations, and Office Operations. The company was founded in 1983 and is headquartered in Chicago, IL.
Read More on VTR:
- Alto Ingredients (ALTO) Receives a Rating Update from a Top Analyst
- H.C. Wainwright Maintains a Buy Rating on Blink Charging Co (BLNK)
- H.C. Wainwright Believes Franco-Nevada (FNV) Still Has Room to Grow
- Tecogen (TGEN) Gets a Buy Rating from H.C. Wainwright
- Analysts Are Bullish on Top Healthcare Stocks: Viridian Therapeutics (VRDN), Geron (GERN)